Supernus Pharmaceuticals, Inc.

27.46 USD
+0.68 (+2.54%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Supernus Pharmaceuticals, Inc. stock is up 15.09% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 11 December’s closed higher than November. 100% of analysts rate it a buy.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the. treatment of epilepsy, as well as for the prophylaxis of migraine headache. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors.